China-based Contract Development and Manufacturing Organization (CDMO) Porton Pharma Solutions Ltd has inaugurated a new research and development (R&D) center in Mengeš, Slovenia, marking a significant step in the company’s global expansion strategy. The investment, totaling €50 million ($54.1 million), encompasses the acquisition and comprehensive renovation of the facility, which now houses approximately 30 staff members. The state-of-the-art facility is equipped with R&D labs, process chemistry, and analytics spaces, and construction of a pilot plant is underway to enable the supply of low-volume active pharmaceutical ingredients (APIs) to clients.
This strategic move follows Porton’s previous announcement of plans to collaborate with Novartis, its API supplier, to establish a bio-park in Mengeš. The new R&D center complements Porton’s extensive network, which spans over 20 sites across China, Europe, and the United States. The company’s most notable international acquisition to date was the 2017 purchase of US-based J-STAR Research, Inc., in a $26 million deal, underscoring its commitment to global growth and innovation.- Flcube.com
